Cephalalgia
How does atogepant compare to rimegepant for migraine prevention?
April 3, 2024
Oral atogepant 60 mg once daily demonstrated a significantly greater reduction in monthly migraine days compared with rimegepant 75 mg orally disintegrating tablet once every other day, with comparable safety profiles.
- Researchers conducted an anchored matching-adjusted indirect comparison analysis using pooled participant-level data from two phase 3 atogepant trials (ADVANCE and PROGRESS) and one phase 2/3 rimegepant trial (BHV3000-305) to evaluate the relative efficacy and safety/tolerability of atogepant and rimegepant as preventive migraine treatments.
- Participants in the included studies received either atogepant 60 mg once daily, rimegepant orally disintegrating tablet 75 mg once every other day, or placebo.
- Only participants meeting the BHV3000-305 inclusion/exclusion criteria were analyzed: ≥6 monthly migraine days and ≤18 monthly headache days at baseline.
- The primary efficacy assessment of interest was change in monthly migraine days across weeks 1-12.
- There were 252 participants in the atogepant group and 348 in the rimegepant group.
- Across weeks 1-12, atogepant 60 mg demonstrated a significantly greater reduction in mean monthly migraine days compared with rimegepant 75 mg (mean difference, -1.65; 95% confidence interval, -2.49 to -0.81; p<0.001).
- Atogepant and rimegepant demonstrated similar safety/tolerability profiles.
epocrates Related Resources:
Source:
Tassorelli C, et al. (2024, February 27). Cephalagia. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. https://pubmed.ncbi.nlm.nih.gov/38410850/
TRENDING THIS WEEK
